KATHERINE MOORE: Open Payments
NPI 1740834316 · WILMINGTON, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$793 in 49 payments from 10 companies in 2025. Trend: 2023 $1,275 · 2024 $1,785 · 2025 $793
Food & beverage: $793
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 6 | $254 |
| ABBVIE INC. | 19 | $209 |
| Novo Nordisk Inc | 13 | $147 |
| Janssen Biotech, Inc. | 2 | $46 |
| Phathom Pharmaceuticals, Inc. | 3 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
| Amgen Inc. | 1 | $14 |
Products named: REZDIFFRA, Ozempic, SKYRIZI, QULIPTA, TREMFYA, UBRELVY, VOQUEZNA, ENTYVIO.
Industry payments across OH — which companies pay providers there.
